Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25144018 | 1.00 | ATM (0.36) | ATMLMNASMN1; SMN2POLBHPGD | |
| SCHEMBL25144026 | 1.00 | ATM (0.36) | ATMLMNASMN1; SMN2POLBHPGD | |
| SCHEMBL18501697 | 0.89 | ATM (0.34) | ATMSMN1; SMN2 | |
| SCHEMBL18501702 | 0.88 | LMNA (0.35) | ATMLMNASMN1; SMN2HPGD | |
| SCHEMBL27022612 | 0.86 | HPGD (0.41) | LMNASMN1; SMN2HPGD | |
| SCHEMBL27022571 | 0.86 | HPGD (0.41) | LMNASMN1; SMN2HPGD | |
| SCHEMBL27022614 | 0.86 | HPGD (0.41) | LMNASMN1; SMN2HPGD | |
| SCHEMBL27421115 | 0.86 | LMNA (0.34) | ATMLMNASMN1; SMN2HPGD | |
| SCHEMBL18501700 | 0.83 | ATM (0.45) | ATMPOLB | |
| SCHEMBL27022583 | 0.83 | HPGD (0.44) | LMNASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809602-B2 | Compounds for treating viral infections | INSTITUT PASTEUR KOREA (KR) | 2017-11-07 | — | — | US | disclosed |
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | INSTITUT PASTEUR KOREA (KR) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, EIF2AK2 | ATM 4209/4885LMNA 4414/4885SMN1; SMN2 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.